Department of Neurology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, South Korea.
J Neurol. 2024 May;271(5):2684-2693. doi: 10.1007/s00415-024-12232-4. Epub 2024 Feb 20.
The effectiveness of endovascular treatment for in-hospital stroke remains debatable. We aimed to compare the outcomes between patients with in-hospital stroke and community-onset stroke who received endovascular treatment.
This prospective registry-based cohort study included consecutive patients who underwent endovascular treatment from January 2013 to December 2022 and were registered in the Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy study and Yonsei Stroke Cohort. Functional outcomes at day 90, radiological outcomes, and safety outcomes were compared between the in-hospital and community-onset groups using logistic regression and propensity score-matched analysis.
Of 1,219 patients who underwent endovascular treatment, 117 (9.6%) had in-hospital stroke. Patients with in-hospital onset were more likely to have a pre-stroke disability and active cancer than those with community-onset. The interval from the last known well to puncture was shorter in the in-hospital group than in the community-onset group (155 vs. 355 min, p<0.001). No significant differences in successful recanalization or safety outcomes were observed between the groups; however, the in-hospital group exhibited worse functional outcomes and higher mortality at day 90 than the community-onset group (all p<0.05). After propensity score matching including baseline characteristics, functional outcomes after endovascular treatment did not differ between the groups (OR: 1.19, 95% CI 0.78-1.83, p=0.4). Safety outcomes did not significantly differ between the groups.
Endovascular treatment is a safe and effective treatment for eligible patients with in-hospital stroke. Our results will help physicians in making decisions when planning treatment and counseling caregivers or patients.
血管内治疗院内卒中的效果仍存在争议。我们旨在比较接受血管内治疗的院内卒中和社区发病卒中的患者的结局。
本前瞻性基于登记的队列研究纳入了 2013 年 1 月至 2022 年 12 月期间在 Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy 研究和延世卒中队列中接受血管内治疗并登记的连续患者。采用逻辑回归和倾向评分匹配分析比较院内组和社区组的 90 天功能结局、影像学结局和安全性结局。
在 1219 例接受血管内治疗的患者中,有 117 例(9.6%)为院内卒中。与社区发病组相比,院内发病组患者更有可能存在卒中前残疾和活动性癌症。院内组从最后一次已知良好状态到穿刺的时间间隔短于社区组(155 分钟 vs. 355 分钟,p<0.001)。两组在血管再通成功或安全性结局方面无显著差异;然而,院内组的 90 天功能结局和死亡率均差于社区组(均 p<0.05)。在包括基线特征的倾向评分匹配后,血管内治疗后的功能结局在两组间无差异(OR:1.19,95%CI 0.78-1.83,p=0.4)。安全性结局在两组间无显著差异。
血管内治疗是一种安全有效的治疗方法,适用于符合条件的院内卒中患者。我们的研究结果将有助于医生在制定治疗计划和向护理人员或患者提供咨询时做出决策。